Ossiam Purchases 1,774 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ossiam lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 10,687 shares of the biopharmaceutical company’s stock after buying an additional 1,774 shares during the period. Ossiam’s holdings in Regeneron Pharmaceuticals were worth $6,141,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Larson Financial Group LLC raised its holdings in Regeneron Pharmaceuticals by 19.1% in the second quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 18 shares in the last quarter. Summit X LLC grew its stake in shares of Regeneron Pharmaceuticals by 0.9% during the second quarter. Summit X LLC now owns 2,352 shares of the biopharmaceutical company’s stock worth $1,306,000 after acquiring an additional 20 shares during the last quarter. Westhampton Capital LLC grew its stake in shares of Regeneron Pharmaceuticals by 2.5% during the second quarter. Westhampton Capital LLC now owns 818 shares of the biopharmaceutical company’s stock worth $457,000 after acquiring an additional 20 shares during the last quarter. Zions Bancorporation N.A. grew its stake in shares of Regeneron Pharmaceuticals by 66.7% during the first quarter. Zions Bancorporation N.A. now owns 55 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 22 shares during the last quarter. Finally, Kingsview Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.7% during the first quarter. Kingsview Wealth Management LLC now owns 651 shares of the biopharmaceutical company’s stock worth $309,000 after acquiring an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 82.31% of the company’s stock.

In related news, CFO Robert E. Landry sold 364 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 9th. The stock was sold at an average price of $617.83, for a total transaction of $224,890.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Leonard S. Schleifer sold 200,000 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 18th. The stock was sold at an average price of $650.03, for a total value of $130,006,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 304,558 shares of company stock worth $194,944,747. Company insiders own 11.84% of the company’s stock.

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $831.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, October 4th. Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $675.00 to $690.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 15th. Royal Bank of Canada upped their target price on Regeneron Pharmaceuticals from $629.00 to $679.00 and gave the stock a “sector perform” rating in a research note on Friday, July 23rd. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $606.00 to $571.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $669.00 to $706.00 and gave the company an “outperform” rating in a research note on Tuesday, September 21st. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $691.76.

Shares of REGN stock traded up $7.44 during midday trading on Thursday, hitting $554.56. The company had a trading volume of 2,161 shares, compared to its average volume of 859,127. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.57 and a quick ratio of 3.04. Regeneron Pharmaceuticals, Inc. has a 52-week low of $441.00 and a 52-week high of $686.62. The stock has a market cap of $59.31 billion, a price-to-earnings ratio of 9.82, a PEG ratio of 0.77 and a beta of 0.16. The company’s 50 day simple moving average is $628.24 and its 200 day simple moving average is $561.38.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported $25.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $8.81 by $16.99. Regeneron Pharmaceuticals had a return on equity of 50.43% and a net margin of 50.11%. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $3.90 billion. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 51.91 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Featured Story: Stock Symbols Definition, Examples, Lookup

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.